- Home
- QNST vs SNDX Comparison
QNST vs SNDX Comparison
Compare QNST & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNST
- SNDX
- Stock Information
- Founded
- QNST 1999
- SNDX 2005
- Country
- QNST United States
- SNDX United States
- Employees
- QNST N/A
- SNDX N/A
- Industry
- QNST Business Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- QNST Consumer Discretionary
- SNDX Health Care
- Exchange
- QNST Nasdaq
- SNDX Nasdaq
- Market Cap
- QNST 1.1B
- SNDX 1.1B
- IPO Year
- QNST 2010
- SNDX 2016
- Fundamental
- Price
- QNST $15.68
- SNDX $10.99
- Analyst Decision
- QNST Strong Buy
- SNDX Strong Buy
- Analyst Count
- QNST 7
- SNDX 11
- Target Price
- QNST $28.29
- SNDX $35.91
- AVG Volume (30 Days)
- QNST 791.7K
- SNDX 2.3M
- Earning Date
- QNST 05-07-2025
- SNDX 05-05-2025
- Dividend Yield
- QNST N/A
- SNDX N/A
- EPS Growth
- QNST N/A
- SNDX N/A
- EPS
- QNST N/A
- SNDX N/A
- Revenue
- QNST $1,029,978,000.00
- SNDX $43,722,000.00
- Revenue This Year
- QNST $80.76
- SNDX $263.44
- Revenue Next Year
- QNST $9.11
- SNDX $129.44
- P/E Ratio
- QNST N/A
- SNDX N/A
- Revenue Growth
- QNST 88.81
- SNDX N/A
- 52 Week Low
- QNST $14.39
- SNDX $9.66
- 52 Week High
- QNST $26.27
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- QNST 41.57
- SNDX 41.30
- Support Level
- QNST $14.69
- SNDX $9.67
- Resistance Level
- QNST $19.29
- SNDX $11.48
- Average True Range (ATR)
- QNST 0.85
- SNDX 0.93
- MACD
- QNST -0.17
- SNDX -0.25
- Stochastic Oscillator
- QNST 21.52
- SNDX 28.96
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.